十一月 18, 2024

Login to your account

Username *
Password *
Remember Me
Image
Program Agenda 2022 高雄國際癌症研討會
04 月 23 日 (星期六) Saturday , 23 April
Time Topic Speaker Moderator
07:30 Registration
08:15-08:30 Opening Remarks
08:30-09:00 Recent development in breast cancer
research in CMU
Mien-Chie Hung
洪明奇
Ming-Feng Hou
侯明鋒
09:00-09:30 Androgen regulated microRNA-887 targets
cation channel TMEM38B to enhance
breast cancer growth and metastasis.
Lu-Hai Wang
王陸海
Mien-Chie Hung
洪明奇
09:30-10:00 ROS-modulating natural products show
antiproliferation to breast cancer cells
Hsueh-Wei Chang
張學偉
Lu-Hai Wang
王陸海
10:00-10:30 Pre-existing anti-polyethylene glycol
antibody reduces the therapeutic efficacy
and pharmacokinetics of PEGylated
liposomes
Tian-Lu Cheng
鄭添祿
Shyng-Shiou Yuan
袁行修
10:30-10:50 Coffee Break
10:50-11:20 Bone Health Care in Patients with Breast
Cancer
Chi-Cheng Huang
黃其晟
King-Jen Chang
張金堅
11:20-11:50 From consistent OS benefit to clinical
practice of current HR+ HER2- mBC
treatment strategy with CDK4/6i
Chun-Yu Liu
劉峻宇
Ling-Ming Tseng
曾令民
11:50-12:20 New Era of Endocrine therapy in HR+
HER2- Advanced Breast Cancer
Ta-Chung Chao
趙大中
Shin-Cheh Chen
陳訓徹
12:20-13:30 Lunc

13:30-14:00 Novel Trop-2 ADC Sacituzumab Govitecan
in cancer therapy
Wei-Pang Chung
鍾為邦
Jyh-Cherng Yu
俞志誠
Dar-Ren Chen
陳達人
14:00-14:30 New role of immunotherapy in triple
negative breast cancer: from late to early
Rina Hui Chiun-Sheng Huang
黃俊升
Yen-Shen Lu
盧彥伸
14:30-15:00 Emerging Evidence with
Immuno-Oncology in TNBC
Kun-Ming Rau
饒坤銘
Shyr-Ming
Sheen-Chen
沈陳石銘
15:00-15:30 Talazoparib in patients with
HER2-advanced breast cancer and a
germline BRCA1/2 mutation: Experience
from clinical trial to real-world study
Kyung-Hun Lee Tsui-Fen Cheng
鄭翠芬
Yao-Lung Kuo
郭耀隆
15:30-16:00 PARB inhibitor, a partner or unitary in
breast cancer treatment?
Jun-Ping Shiau
蕭君平
Shou-Tung Chen
陳守棟
16:00-16:20 Coffee Break
16:20-16:50 The role of pegylated liposomal
doxorubicin as adjuvant and neoadjuvant in
early breast cancer
Chi-Cheng Huang
黃其晟
Ming-Yang Wang
王明暘
Guo-Shiou Liao
廖國秀
16:50-17:20 Transforming clinical treatment in HER2
Positive Breast Cancer with PHESGO
An-Chieh Feng
馮安捷
Ming-Shen Dai
戴明燊
Dah-Cherng Yeh
葉大成
17:20-17:50 Focus on HER2+ mBC patients
How to Change Her Destiny by Novel
ADC Therapy?
Liang-Chih Liu
劉良智
Hsien-Kun Chang
張献崑
17:50-18:00 Panel Discussion & Closing



Program Agenda 2022 高雄國際癌症研討會
04 月 24 日 (星期日) Sunday , 24 April
Time Topic Speaker Moderator
08:30-09:00 Bridging the gap: ABC6 (Advance Breast
Cancer) and ABC Global Alliance
Shinji Ohno
大野真司
Hong-Tai Chang
張宏泰
Ching-Kuen Pan
潘慶坤
09:00-09:30 Is HER2-lopositive or ER-low-positive new
subtype of triple negative breast cancer?
Takashi Ishikawa
石川孝
Chao-Ming Hung
洪朝明
Kun-Ming Rau
饒坤銘
09:30-10:00 Treatment strategy update for MBCs post
CDK4/6 inhibitors
Tetsu Hayashida
林田哲
Chen-Hsiang Chang
張振祥
Kuo-Ting Lee
李國鼎
10:30-10:50 Coffee Break
10:20-10:50 Breast Cancer Risks among Female Health
Professionals
Hui-Min Hsieh
謝慧敏
Chih-Jen Huang
黃志仁
10:50-11:20 Gut microbiota in premenopausal breast
cancer: from the perspective of prevention,
detection, and treatment response
Chih-Po Chiang
江誌博
Ming-Yii Huang
黃旼儀
11:20-11:50 Dissecting the expression of epigenetic
modulator as a guideline for determining
combined RT therapy in LN+ TNBC
patients
Mei-Ren Pan
潘美仁
Fu Ou-Yang
歐陽賦
11:50-12:20 Targeting focal adhesion kinase as an
alternative antiangiogenesis therapy in
triple-negative breast cancer
Chi-Wen Luo
羅啟文
Shen-Liang Shih
施昇良
12:20-12:30 Closing Fang-Ming Chen
陳芳銘

醫院門口管制措施:

(1) 高醫體系醫院人員:

攜帶 "醫院識別證 (員工通道)" or "健保卡/身分證 (民眾通道)",過卡驗證成功後才可入院。

 

(2) 高雄醫學大學人員:

報名時須填正確 "身分證字號",由大會協助登入「來院人員登錄系統 」

以"健保卡/身分證 (民眾通道)"驗證,驗證成功後才可入院。

並配合最新防疫規定:需檢附疫苗接種紀錄 (2劑 or 3劑)或 參與日前3日內採檢陰性報告(核酸或抗原)。

 

(3) 院外人員:

報名時須填正確 "身分證字號",由大會協助登入「來院人員登錄系統 」

以"健保卡/身分證 (民眾通道)"驗證,驗證成功後才可入院。

並配合最新防疫規定:需檢附 疫苗接種紀錄 (2劑 or 3劑)或 參與日前3日內採檢陰性報告(核酸或抗原)

 

最新防疫規定將配合疫情指揮中心,進行滾動式調整。

 
 
 
 
日期 & 時間
2022 年 4 月23 日(六) - 4月 24 日(日)
Last modified on 週日, 06 十一月 2022 07:02